{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T02:01:35Z","timestamp":1790733695943,"version":"4.1.0"},"reference-count":46,"publisher":"American Society for Microbiology","issue":"2","license":[{"start":{"date-parts":[[2016,1,29]],"date-time":"2016-01-29T00:00:00Z","timestamp":1454025600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2016,2]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    Toxicity has emerged during the clinical development of many but not all nucleotide inhibitors (NI) of hepatitis C virus (HCV). To better understand the mechanism for adverse events, clinically relevant HCV NI were characterized in biochemical and cellular assays, including assays of decreased viability in multiple cell lines and primary cells, interaction with human DNA and RNA polymerases, and inhibition of mitochondrial protein synthesis and respiration. NI that were incorporated by the mitochondrial RNA polymerase (PolRMT) inhibited mitochondrial protein synthesis and showed a corresponding decrease in mitochondrial oxygen consumption in cells. The nucleoside released by the prodrug balapiravir (R1626), 4\u2032-azido cytidine, was a highly selective inhibitor of mitochondrial RNA transcription. The nucleotide prodrug of 2\u2032-\n                    <jats:italic>C<\/jats:italic>\n                    -methyl guanosine, BMS-986094, showed a primary effect on mitochondrial function at submicromolar concentrations, followed by general cytotoxicity. In contrast, NI containing multiple ribose modifications, including the active forms of mericitabine and sofosbuvir, were poor substrates for PolRMT and did not show mitochondrial toxicity in cells. In general, these studies identified the prostate cell line PC-3 as more than an order of magnitude more sensitive to mitochondrial toxicity than the commonly used HepG2 cells. In conclusion, analogous to the role of mitochondrial DNA polymerase gamma in toxicity caused by some 2\u2032-deoxynucleotide analogs, there is an association between HCV NI that interact with PolRMT and the observation of adverse events. More broadly applied, the sensitive methods for detecting mitochondrial toxicity described here may help in the identification of mitochondrial toxicity prior to clinical testing.\n                  <\/jats:p>","DOI":"10.1128\/aac.01922-15","type":"journal-article","created":{"date-parts":[[2015,11,23]],"date-time":"2015-11-23T21:43:29Z","timestamp":1448315009000},"page":"806-817","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":82,"title":["Role of Mitochondrial RNA Polymerase in the Toxicity of Nucleotide Inhibitors of Hepatitis C Virus"],"prefix":"10.1128","volume":"60","author":[{"given":"Joy Y.","family":"Feng","sequence":"first","affiliation":[{"name":"Gilead Sciences, Foster City, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yili","family":"Xu","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Foster City, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ona","family":"Barauskas","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Foster City, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason K.","family":"Perry","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Foster City, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shekeba","family":"Ahmadyar","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Foster City, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Stepan","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Foster City, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Yu","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Foster City, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darius","family":"Babusis","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Foster City, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeojin","family":"Park","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Foster City, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krista","family":"McCutcheon","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Foster City, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Perron","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Foster City, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian E.","family":"Schultz","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Foster City, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roman","family":"Sakowicz","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Foster City, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian S.","family":"Ray","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Foster City, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2010.03432.x"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.3851\/IMP2424"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2010.02391.x"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkn085"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01317-07"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1517\/13543780902854194"},{"key":"e_1_3_3_8_2","volume-title":"Press release","author":"Pharmasset","year":"2011","unstructured":"Pharmasset. 16 December 2011. Pharmasset announces intent to amend Quantum trial. Press release. Pharmasset, Princeton, NJ. http:\/\/www.sec.gov\/Archives\/edgar\/data\/1301081\/000119312511344160\/d270472dex991.htm."},{"key":"e_1_3_3_9_2","volume-title":"General release","author":"Idenix Pharmaceuticals","year":"2013","unstructured":"Idenix Pharmaceuticals. 4 February 2013. Idenix Pharmaceuticals provides update on IDX184 and IDX19368 development programs. General release. Idenix Pharmaceuticals, Cambridge, MA. http:\/\/globenewswire.com\/news-release\/2013\/02\/04\/520696\/10020506\/en\/Idenix-Pharmaceuticals-Provides-Update-on-IDX184-and-IDX19368-Development-Programs.html."},{"key":"e_1_3_3_10_2","unstructured":"Bristol-Myers Squibb. 23 August 2012. Bristol-Myers Squibb discontinues development of BMS-986094 an investigational NS5B nucleotide for the treatment of hepatitis C. Press release. Bristol-Myers Squibb New York NY. http:\/\/news.bms.com\/press-release\/financial-news\/bristol-myers-squibb-discontinues-development-bms-986094-investigationa."},{"key":"e_1_3_3_11_2","unstructured":"Vertex Pharmaceuticals Incorporated. July 25 2013. Vertex provides update on ongoing all-oral studies of VX-135 in hepatitis C. Press release. Vertex Pharmaceuticals Inc. Cambridge MA. http:\/\/investors.vrtx.com\/releasedetail.cfm?ReleaseID=780456."},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01032-08"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1003030"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02351-13"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.24.24.10636-10649.2004"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/toxsci\/kfg188"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1021\/mp900036s"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.273.2.1257"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1101\/gad.11.10.1315"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2015.04.073"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(19)43117-7"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1021\/bi00640a028"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ab.2010.04.040"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10863-012-9446-z"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.freeradbiomed.2011.08.005"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-10-1728"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(04)00120-5"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature10435"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00399-10"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm400201a"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27488"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pharmtox-010510-100228"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0925-4439(02)00092-3"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199510263331702"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M106743200"},{"key":"e_1_3_3_36_2","first-page":"77","article-title":"Depletion of mitochondrial DNA, destruction of mitochondria, and accumulation of lipid droplets result from fialuridine treatment in woodchucks (Marmota monax)","volume":"76","author":"Lewis W","year":"1997","unstructured":"Lewis W, Griniuviene B, Tankersley KO, Levine ES, Montione R, Engelman L, de Courten-Myers G, Ascenzi MA, Hornbuckle WE, Gerin JL, Tennant BC. 1997. Depletion of mitochondrial DNA, destruction of mitochondria, and accumulation of lipid droplets result from fialuridine treatment in woodchucks (Marmota monax). Lab Invest 76:77\u201387.","journal-title":"Lab Invest"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrd1201"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.38.8.1824"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.10.3944-3953.2004"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1093\/toxsci\/kfm052"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01335-10"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01101-10"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1136\/sti.77.3.158"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2011.05.003"},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(95)70275-X"},{"key":"e_1_3_3_46_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-116-4-311"},{"key":"e_1_3_3_47_2","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1007\/BF00788231","article-title":"Chloramphenicol toxicity associated with severe cardiac dysfunction","volume":"13","author":"Suarez CR","year":"1992","unstructured":"Suarez CR, Ow EP. 1992. Chloramphenicol toxicity associated with severe cardiac dysfunction. Pediatr Cardiol 13:48\u201351.","journal-title":"Pediatr Cardiol"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01922-15","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01922-15","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,15]],"date-time":"2023-08-15T19:19:08Z","timestamp":1692127148000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.01922-15"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2]]},"references-count":46,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["10.1128\/AAC.01922-15"],"URL":"https:\/\/doi.org\/10.1128\/aac.01922-15","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.725957628.793512777","asserted-by":"object"}]},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2]]},"assertion":[{"value":"2015-08-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-11-13","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-01-29","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}